Cemdisiran - Alnylam Pharmaceuticals
Alternative Names: AD-62643; ALN 62643; ALN-CC5Latest Information Update: 12 Nov 2024
At a glance
- Originator Alnylam Pharmaceuticals
- Developer Alnylam Pharmaceuticals; Regeneron Pharmaceuticals
- Class Drug conjugates; Oligonucleotides; Small interfering RNA
- Mechanism of Action Complement C5 inhibitors; RNA interference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Dry macular degeneration; Myasthenia gravis; Paroxysmal nocturnal haemoglobinuria
- Phase II Haemolytic uraemic syndrome; IgA nephropathy
Most Recent Events
- 31 Oct 2024 Phase-III clinical trials in Dry macular degeneration (Combination therapy) (SC) prior to October 2024 (NCT06541704)
- 31 Oct 2024 Phase-III clinical trials in Dry macular degeneration (Monotherapy) (SC) prior to October 2024 (NCT06541704)
- 07 Aug 2024 Regeneron Pharmaceuticals plans a phase III SIENNA trial for Geographic atrophy (Monotherapy, Combination therapy) in October 2024 (NCT06541704) (SC, Injection)